老年多重用药患者抗胆碱能负荷:DBI、ACB 与 Duran 量表在初级保健中的比较
Anticholinergic burden in older adults with hyperpolypharmacy: a comparison of the drug burden index, anticholinergic cognitive burden, and duran scales in primary care
一项纳入 6,550 例 ≥ 65 岁、用药 ≥ 10 种的初级保健患者的多中心横断面研究显示,83.3% 至少被处方一种具抗胆碱能活性药物;DBI 判定 50.2% 为高负荷、44.2% 为中等,而 ACB 量表仅 24.8%、Duran 量表 27.2% 为高风险。
- Article
- Open access
- Published: 03 October 2026
Scientific Reports (2026) Cite this article
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Abstract
To evaluate anticholinergic burden in older adults (≥ 65 years) with hyperpolypharmacy (≥ 10 medications) in primary care using the Drug Burden Index (DBI), and to compare the results with those obtained using the Anticholinergic Cognitive Burden (ACB) scale and Duran’s scale. Additionally, factors associated with increased anticholinergic burden were explored. A multicenter cross-sectional study was conducted including 6,550 patients aged ≥ 65 years with hyperpolypharmacy in primary care settings. Sociodemographic, clinical, functional, and pharmacotherapeutic variables were obtained from electronic health records. Anticholinergic burden was assessed using the DBI, ACB, and Duran’s scales. Differences in burden according to patient characteristics were analyzed. Overall, 83.3% of patients were prescribed at least one medication with anticholinergic activity. According to the DBI, 50.2% of patients were classified as having a high anticholinergic burden, 44.2% as moderate burden, and 5.6% as having no risk. In contrast, the ACB scale classified 24.8% of patients as high risk, while Duran’s scale identified 27.2% as high risk. Mean DBI values were significantly higher among women, patients with dementia, individuals with greater cognitive and functional impairment, and those receiving ≥ 15 medications. Lorazepam and tramadol were the most frequently prescribed medications contributing to anticholinergic burden. Anticholinergic burden in older adults with hyperpolypharmacy varies substantially depending on the assessment tool used. The DBI identified a considerably higher burden than the ACB and Duran’s scales, reflecting important methodological differences among instruments. Systematic assessment of anticholinergic burden and regular medication review may help optimize pharmacotherapy and improve medication safety in this vulnerable population.
Abbreviations
- AAS:
-
Anticholinergic Activity Scale
- ABC:
-
Anticholinergic Burden Classification
- ACB:
-
Anticholinergic Cognitive Burden
- ADS:
-
Anticholinergic Drug Scale
- ALS:
-
Anticholinergic Load Scale
- ARS:
-
Anticholinergic Risk Scale
- ATC:
-
Anatomical Therapeutic Chemical
- CrAS:
-
Clinician-Rated Anticholinergic Scale
- DBI:
-
Drug Burden Index
- eCAP:
-
electronic Clinical Station in Primary Care Health Records Database
- F:
-
Female
- ICD:
-
International Classification of Disease
- M:
-
Male
- SD:
-
Standard Deviation
Author information
Authors and Affiliations
Clinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and Pharmaceutical Technology, Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, Barcelona, 08028, Spain
María José Sarria Arroyo, Antonio J. Braza, Montserrat Viñas-Bastart & Pilar Modamio
Delta Primary Care and Community Care Management, Departament de Salut. Generalitat de Catalunya, Institut Català de la Salut, Plaça de l’Aigua, 3, 1a planta, El Prat de Llobregat. Barcelona, 08820, Spain
Gemma Rodríguez Palomar & Neus Parellada Esquius
Authors
- María José Sarria Arroyo
- Gemma Rodríguez Palomar
- Neus Parellada Esquius
- Antonio J. Braza
- Montserrat Viñas-Bastart
- Pilar Modamio
Corresponding authors
Correspondence to Antonio J. Braza or Pilar Modamio.
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of the Primary Health Care Research Institute Jordi Gol i Gurina (Institut Universitari d’Investigació en Atenció Primària Jordi Gol i Gurina, IDIAPJGol) (reference 21/123-P). The requirement for informed consent was waived by the Clinical Research Ethics Committee of the Primary Health Care Research Institute Jordi Gol i Gurina (IDIAPJGol) (reference 21/123-P), because this was a retrospective cross-sectional study based exclusively on anonymized data.
Consent for publication
All authors agreed to the publication of this manuscript.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appendices
ANNEX 1. Population description of anticholinergic scales
Variable | Frequency (no. of patients) | Percentage (%) |
|---|---|---|
DBI Scale | ||
0 (No risk | 303 | 5.6 |
<1 (Moderate) | 2410 | 44.2 |
≥ 1 (High) | 2742 | 50.2 |
Duran’s Scale | ||
0 (No risk) | 1996 | 36.6 |
1 (Moderate) | 1976 | 36.2 |
≥ 2 (High) | 1483 | 27.2 |
ACB Scale | ||
0 (No risk | 2878 | 52.8 |
1 (Low) | 1004 | 18.4 |
2 (Moderate) | 220 | 4.0 |
≥ 3 (High) | 1353 | 24.8 |
ANNEX 2. Prescribed medicines whose drugs have anticholinergic activity in DBI scale and anticholinergic load values on the ACB and Duran’s scales
Drug DBI scale*21 | ATC | No. patients (%) | ACB scale** 21 | Duran’s scale*** 3 |
|---|---|---|---|---|
Lorazepam | N05BA06 | 1364 (25.0) | 1 | 0 |
Tramadol | N02AX02 | 1068 (19.58) | 0 | 1 |
Sertraline | N06AB06 | 721 (13.22) | 0 | 1 |
Pregabalin | N03AX16 | 654 (11.99) | 0 | 0 |
Tamsulosin | G04CA02 | 646 (11.84) | 0 | 0 |
Quetiapine | N05AH04 | 601 (11.02) | 3 | 1 |
Diazepam | N05BA01 | 490 (8.98) | 1 | 1 |
Citalopram | N06AB04 | 478 (8.76) | 0 | 1 |
Trazodone | N06AX05 | 477 (8.74) | 1 | 1 |
Mirtazapine | N06AX11 | 431 (7.90) | 0 | 1 |
Doxazosin | C02CA04 | 430 (7.88) | 0 | 0 |
Transdermal Fentanyl | N02AB03 | 387 (7.09) | 1 | 1 |
Venlafaxine | N06AX16 | 343 (6.29) | 0 | 0 |
Gabapentin | N03AX12 | 320 (5.87) | 0 | 0 |
Paroxetine | N06AB05 | 308 (5.65) | 3 | 1 |
Amitriptyline | N06AA09 | 268 (4.91) | 3 | 1 |
Alprazolam | N05BA12 | 261 (4.78) | 1 | 0 |
Clonazepam | N03AE01 | 259 (4.75) | 0 | 1 |
Dutasteride + Tamsulosin | G04CA52 | 190 (3.48) | 0 | 0 |
Cetirizine | R06AE07 | 188 (3.45) | 0 | 1 |
Fluoxetine | N06AB03 | 142 (2.60) | 0 | 1 |
Risperidone | N05AX08 | 132 (2.42) | 1 | 1 |
Escitalopram | N06AB10 | 124 (2.27) | 0 | 0 |
Zolpidem | N05CF02 | 118 (2.16) | 0 | 0 |
Solifenacin | G04BD08 | 117 (2.14) | 3 | 2 |
Silodosin | G04CA04 | 100 (1.83) | 0 | 0 |
Levetiracetam | N03AX14 | 96 (1.76) | 0 | 0 |
Clorazepate | N05BA05 | 93 (1.70) | 1 | 0 |
Pramipexol | N04BC05 | 93 (1.70) | 0 | 0 |
Solifenacin + Tamsulosin | G04CA53 | 69 (1.26) | 0 | 0 |
Loratadine | R06AX13 | 67 (1.23) | 0 | 1 |
Olanzapine | N05AH03 | 58 (1.06) | 3 | 1 |
Oxycodone/Naloxone | N02AA55 | 58 (1.06) | 0 | 0 |
Metoclopramide | A03FA01 | 57 (1.04) | 0 | 0 |
Intravenous Morphine | N02AA01 | 57 (1,04) | 1 | 1 |
Fesoterodine | G04BD11 | 55 (1.01) | 0 | 0 |
Clomipramine | N06AA04 | 52 (0.95) | 3 | 1 |
Valproic Acid | N03AG01 | 49 (0.90) | 0 | 0 |
Carbamazepine | N03AF01 | 46 (0.84) | 2 | 1 |
Tolterodine | G04BD07 | 40 (0.73) | 3 | 2 |
Haloperidol | N05AD01 | 39 (0.71) | 1 | 1 |
Lamotrigine | N03AX09 | 38 (0.70) | 0 | 0 |
Codeine Associations | N02AA59 | 36 (0.66) | 2 | 0 |
Hydroxyzine | N05BB01 | 33 (0.60) | 3 | 2 |
Primidone | N03AA03 | 30 (0.55) | 0 | 0 |
Baclofen | M03BX01 | 26 (0.48) | 0 | 1 |
Ropinirole | N04BC04 | 24 (0.44) | 0 | 0 |
Aripiprazole | N05AX12 | 22 (0.40) | 0 | 0 |
Lithium | N05AN01 | 19 (0.35) | 0 | 1 |
Oxybutynin | G04BD04 | 19 (0.35) | 3 | 2 |
Phenobarbital | N03AA02 | 18 (0.33) | 0 | 1 |
Amitriptyline/Medazepam | N06CA92 | 17 (0.31) | 0 | 0 |
Dexchlorpheniramine | R06AB52 | 17 (0.31) | 0 | 2 |
Phenytoin | N03AB02 | 17 (0.31) | 0 | 0 |
Oxcarbazepine | N03AF02 | 16 (0.29) | 2 | 1 |
Alfuzosin | G04CA01 | 15 (0.27) | 0 | 0 |
Cyclobenzaprine | M03BX08 | 12 (0.22) | 2 | 1 |
Metoclopramide/Dimethicone | A03FA | 12 (0.22) | 0 | 0 |
Diazepam/Pyridoxine | N05BA/A11HA | 10 (0.18) | 0 | 0 |
Levocetirizine | R06AE09 | 10 (0.18) | 0 | 1 |
Oxycodone | N02AA05 | 10 (0.18) | 0 | 1 |
Tizanidine | M03BX02 | 9 (0.16) | 0 | 2 |
Imipramine | N06AA02 | 8 (0.15) | 3 | 2 |
Terazosin | G04CA03 | 7 (0.13) | 0 | 0 |
Loperamide | A07DA03 | 6 (0.11) | 1 | 1 |
Nortriptyline | N06AA10 | 6 (0.11) | 3 | 2 |
Paliperidone | N05AX13 | 6 (0.11) | 0 | 0 |
Trospium | G04BD09 | 5 (0.09) | 0 | 0 |
Clonidine | C02AC01 | 4 (0.07) | 0 | 0 |
Flurazepam | N05CD01 | 3 (0.05) | 0 | 0 |
Hydromorphone | N02AA03 | 3 (0.05) | 0 | 0 |
Methocarbamol | M03BA03 | 3 (0.05) | 0 | 1 |
Trihexyphenidyl | N04AA01 | 3 (0.05) | 3 | 2 |
Asenapine | N05AH05 | 2 (0.04) | 0 | 0 |
Doxepin | N06AA12 | 2 (0.04) | 3 | 2 |
Prazosin | C02CA01 | 2 (0.04) | 0 | 0 |
Dextromethorphan | R05DA09 | 1 (0.02) | 0 | 0 |
Dextromethorphan/Diphenhydramine | R05DA20 | 1 (0.02) | 0 | 2 |
Diphenhydramine | D04AA32 | 1 (0.02) | 0 | 2 |
Disopyramide | C01BA03 | 1 (0.02) | 1 | 1 |
Methadone | N07BC02 | 1 (0.02) | 0 | 1 |
Methocarbamol/Paracetamol | M03BA53 | 1 (0.02) | 0 | 1 |
Perphenazine | N05AB04 | 1 (0.02) | 3 | 0 |
Pimozide | N05AG02 | 1 (0.02) | 2 | 1 |
Triazolam | N05CD05 | 1 (0.02) | 0 | 1 |
Ziprasidone | N05AE04 | 1 (0.02) | 0 | 0 |
- (*DBI scale: Drug Burden Index: 0 = no risk, < 1 = moderate risk, and ≥ 1 = high risk, **ACB scale: Anticholinergic Cognitive Burden: 0 = no risk, 1 = low risk, 2 = moderate risk, ≥ 3 = high risk. ***Duran’s scale: 0 = no risk, 1 = low risk, ≥ 2 = high risk).
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Arroyo, M.J.S., Palomar, G.R., Esquius, N.P. et al. Anticholinergic burden in older adults with hyperpolypharmacy: a comparison of the drug burden index, anticholinergic cognitive burden, and duran scales in primary care. Sci Rep (2026). https://doi.org/10.1038/s41598-026-73968-9
Received: 27 July 2026
Accepted: 25 September 2026
Published: 03 October 2026
DOI: https://doi.org/10.1038/s41598-026-73968-9
Keywords
来源:Nature 健康护理主题 · nature.com